AMPH — Amphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Full Year Revenue: $719.9 million, a slight decline of 2% year-over-year.
• Q4 Revenue: $183.1 million, down 2% from $186.5 million in Q4 2024.
• Net Income: $24.4 million ($0.51 per share) for Q4 2025, compared to $38 million ($0.74 per share) in Q4 2024.
• Adjusted Net Income: $34.2 million ($0.73 per share), down from $47.2 million ($0.92 per share) in the prior year.
• Operating Cash Flow: $156.1 million for the full year; $32.9 million in Q4.
• Gross Margin: Remained flat at 47% of revenues despite pricing pressures on certain products.

2. Strategic Updates and Business Highlights:

• Product Performance: BAQSIMI generated $185.4 million in revenue, up 12% year-over-year. Primatene MIST sales rose 7% to $108.7 million.
• New Product Approvals: FDA approvals for iron sucrose, teriparatide, and ipratropium bromide HFA inhalation aerosol (AMP-007), the latter expected to launch in Q2 2026.
• Pipeline Expansion: Introduction of three novel peptides in oncology and ophthalmology, and a synthetic corticotropin program in immunology.
• Manufacturing Investment: Expansion at the Rancho Cucamonga facility to quadruple production capacity, enhancing scalability and supply reliability.

3. Forward Guidance and Outlook:

• 2026 Revenue Growth: Expected mid- to high-single-digit growth, driven by BAQSIMI and the launch of ipratropium bromide, offset by declines in glucagon and epinephrine sales.
• Gross Margins: Anticipated to decrease due to pricing pressures and increased input costs.
• R&D Spending: Expected to increase significantly to support clinical trials and the proprietary pipeline.
• Cash Utilization: Plans to continue stock buybacks while also considering business development opportunities.

4. Bad News, Challenges, or Points of Concern:

• Legacy Product Declines: Significant sales declines in glucagon (down 45%) and epinephrine (down 9%) due to increased competition and market shifts towards ready-to-use products.
• Operational Costs: Rising costs in labor and supplier-related expenses are expected to further impact margins.
• International Sales Impact: Planned discontinuation of unprofitable international sales of BAQSIMI may offset U.S. growth.

5. Notable Q&A Insights:

• AMP-110 Development: No FDA discussions yet; internal planning is ongoing.
• Business Development Focus: Interest in assets related to endocrinology, oncology, ophthalmology, and immunology.
• Primatene MIST Competition: No immediate competition expected post-patent expiration; ongoing life cycle management activities are in place.
• Market Dynamics for AMP-007: Potential for market share growth with 180 days of exclusivity, but no visibility on authorized generics.

This summary captures the essential financial metrics, strategic initiatives, future outlook, and challenges faced by Amphastar Pharmaceuticals as discussed in the Q4 2025 earnings call.